Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008733

SCHEMBL1008733

SCHEMBL1008733

N#Cc1ncc(C#Cc2ccccc2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ GRM5 P41594 8/20 0.43
▸ GRM4 Q14833 3/20 0.41
▸ BCAT1 P54687 1/20 0.41
▸ PLAU P00749 1/20 0.40
▸ PLAT P00750 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ APP P05067 1/20 0.40
▸ AKR1C2 P52895 1/20 0.40
▸ AKR1C1 Q04828 1/20 0.40
▸ ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008436 0.87 GRM5 (0.44) KDM4EALDH1A1POLBGRM5BCAT1
SCHEMBL1010354 0.84 GRM5 (0.46) KDM4EALDH1A1POLBGRM5
SCHEMBL19063455 0.79 ALDH1A1 (0.40) KDM4EALDH1A1POLBGRM5BCAT1
SCHEMBL1008935 0.79 KDM4E (0.41) KDM4EALDH1A1POLB
SCHEMBL1007768 0.78 MAPT (0.43) KDM4EALDH1A1POLBGRM5
SCHEMBL2230401 0.77 FFAR1 (0.37) KDM4EALDH1A1POLBGRM5GRM4
SCHEMBL1007760 0.77 ALDH1A1 (0.42) KDM4EALDH1A1
SCHEMBL27877866 0.77 IMPDH2 (0.49) KDM4EALDH1A1POLBPLAUPLAT
SCHEMBL16598517 0.76 ADK (0.47) GRM5GRM4PLAUPLATPDGFRB
SCHEMBL1009701 0.76 ALDH1A1 (0.60) KDM4EALDH1A1POLBBCAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180333406-A1 BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2018-11-22 — — US disclosed
US-9950062-B2 Compounds and compositions as TLR activity modulators GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2018-04-24 — — US disclosed
US-9597326-B2 Benzonapthyridine compositions and uses thereof GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2017-03-21 — — US disclosed
EP-2473508-B1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS NOVARTIS AG (CH) 2017-03-08 — — EP disclosed
US-20150225432-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS NOVARTIS AG (CH) 2015-08-13 — — US disclosed
US-9045470-B2 Compounds and compositions as TLR activity modulators IRM LLC (BM) 2015-06-02 — — US disclosed
EP-2268618-B1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS NOVARTIS AG (CH) 2015-05-27 — — EP disclosed
US-8895577-B2 Compounds and compositions as TLR activity modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2014-11-25 — — US disclosed
EP-2459216-B1 IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS NOVARTIS AG (CH) 2013-10-30 — — EP disclosed
US-20130253002-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2013-09-26 — — US disclosed
US-20120237546-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS NOVARTIS AG (CH) 2012-09-20 — — US disclosed
EP-2473508-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2012-07-11 — — EP disclosed
EP-2459216-A2 IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS Novartis AG (CH) 2012-06-06 — — EP disclosed
WO-2011130379-A1 BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF NOVARTIS AG (CH) 2011-10-20 — — WO disclosed
WO-2011049677-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-04-28 — — WO disclosed
US-20110081365-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-04-07 — — US disclosed
WO-2011027222-A2 IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS NOVARTIS AG (CH) 2011-03-10 — — WO disclosed
US-20110053893-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-03-03 — — US disclosed
EP-2268618-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-01-05 — — EP disclosed
WO-2009111337-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130253002-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS TLR5, TLR8, TLR7 KDM4E 1503/4885ALDH1A1 4772/4885POLB 3962/4885
US-20150225432-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS TLR1, TLR6, TLR7 KDM4E 2884/4885ALDH1A1 4804/4885POLB 3038/4885
US-20120237546-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS TLR1, TLR6, TLR7 KDM4E 2884/4885ALDH1A1 4804/4885POLB 3038/4885
US-20110053893-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS TLR1, TLR6, TLR7 KDM4E 2884/4885ALDH1A1 4804/4885POLB 3038/4885
US-20110081365-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS TLR5, TLR8, TLR7 KDM4E 1503/4885ALDH1A1 4772/4885POLB 3962/4885
US-20180333406-A1 BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF HAMP, MAVS, MYD88 KDM4E 3767/4885ALDH1A1 4543/4885POLB 2979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.